Phase II BYLieve: Alpelisib Plus Fulvestrant in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitor Plus AI

May 29-31, 2020; Online at meetings.asco.org/am
Alpelisib plus fulvestrant demonstrated clinically meaningful efficacy based on the proportion of patients alive without PD at 6 months in this analysis of patients with PIK3CA-mutated HR+/HER2- advanced BC previously treated with CDK4/6i plus AI.
Format: Microsoft PowerPoint (.ppt)
File Size: 234 KB
Released: June 3, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Related Content

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

First-line pembrolizumab + chemotherapy significantly improved OS vs chemotherapy alone in locally recurrent unresectable or metastatic TNBC with PD-L1 CPS ≥10, from ESMO 2021 as reported by Clinical Care Options (CCO)

Released: September 28, 2021

Novel ADC [vic]-trastuzumab duocarmazine significantly prolonged PFS vs physician’s choice treatment in pretreated HER2+ advanced or metastatic breast cancer, presented at ESMO as reported by Clinical Care Options (CCO)

Released: September 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue